Login / Signup

Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial.

Chika AkinseyeCourtney CrimAmy NewlandsDavid Fairman
Published in: PloS one (2023)
Lack of clinical benefits with GSK3772847 was likely due to the small sample size, highlighting the need for larger prospective studies.
Keyphrases
  • double blind
  • phase iii
  • placebo controlled
  • phase ii
  • clinical trial
  • study protocol
  • pi k akt
  • signaling pathway
  • open label
  • minimally invasive
  • high intensity
  • case control
  • cell proliferation